



PROTECTION PROVIDED BY PRRSV MLV (PRRSV1 AND PRRSV2) AGAINST AN ASIAN PRRSV2 FIELD STRAIN

Miranda¹, J.; Romero¹, S.; De Lucas¹, L.; Fenech¹, M.; Saito², F.; Diaz³, I.

¹HIPRA, Amer (Girona), Spain; ² Hipra Japan, Tokyo; ³Universitat Autònoma de Barcelona *Corresponding author: lidia.lucas@hipra.com

Introduction

Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccines have been shown to mitigate the impact of the infection. This study assesses the effectiveness of two commercial live vaccines - based on PRRSV1 (UNISTRAIN® PRRS; HIPRA) and PRRSV2 (strain VR-2332) - against an Asian PRRSV2 field strain.

	0 dpv 7-10-21 dpv		0 dpv (7 woa)	2-4-6-8- 11-13-16 dpi	21 dpv (10 woa)	
G1 (n=5; vaccine PRRSV1 MLV)			*	ETA		
G2 (n=4; vaccine PRRSV2 MLV)		ETH	*	ETA		
INF (n=5; no vaccine)	ETA.	ETH				
CTRL (n=5; no vaccine & no challenge)	ELLIN	ETH	ETA	eth eth		
Samples were submitted to PRRSV ELISA testing (Civtest® Suis ES and AM), PRRSV neutralization testing and PRRSV isolation.	PRRS G1 - F	nation against V: RRSV1 MLV; G2 - V2 MLV	Challenge with an Asian PRRSV2: Strain Chiba NOSAI. Intranasal application: 103,5 TCID50/mL (1mL each nostril) Euthanasia and tissue sample collection: Samples from lungs, tonsils, and lymph nodes (submandibular and bronchial) were submitted to PRRS isolation.			

Table 1. Experimental design. Between 0 and 21days post-infection (dpi), clinical protection was measured daily in terms of clinical signs and rectal temperatures in all groups.




Figure 1. Homology between strains (ORF5). The Asian field strain used to challenge the pigs had a greater homology to the strain VR-2332 (G2).

Results

At necropsy (21 days after the challenge), tissue analysis revealed a similar pattern, with the G1 showing the lowest viral load in tonsils (p<0.05), a common site of viral presence. One animal in that group was negative in all tissues.

	PRRSV i	PRRS in tissues		
	Positives/total	AUC	Positives/total	
G1	19/35b	12.8±7.7b	6/20a	
G2	19/28b	16.2±4.3b	9/16a	
INF	33/35a	22.1±3.5a	11/20a	
CTRL	0/35c	0.0±0.0c	0/20b	

Table 2. Positivity to PRRSV in blood and tissue samples: proportion of positive samples/total group samples and average ± SD of virus titers. AUC - Area Under de Curve. Superscript letters show significant differences among groups.




Figure 2. Average rectal temperature in all groups between 0 and 21 dpi.

	PRRSV2-MLV specific-NA (dpv)					PRRSV2-MLV specific-NA (dpv)						
Group	0	7	14	21	28 (0 dpi)	21 (0 dpi)	0	7	14	21	28 (0 dpi)	21 (0 dpi)
G1	-	-	-	-	-	-	-	-	2/5 1.0±1.7	3/5 1.4±1.7	4/5 2.0±1.4	5/5 4.4±2.1 ^a
G2	-	-	-	-	-	4/4 2.2±0.5		-	-	-	-	-
INF	-	-	-	-	-	-	-	-	-	-	-	-
CTRL	-	-	-	-	-	-	-	-	-	-	-	_

Table 3. Viral neutralization test results. Proportion of positive samples and average ± SD of titers (log2). The Friedman test was used to compare kinetics inside group G1.

dpv, days post-vaccination; dpi, days post-infection; PRRSV, porcine reproductive and respiratory syndrome virus; MLV, modified-live vaccine; NA, neutralizing antibodies.

Discussion & Conclusion

UNISTRAIN® PRRS, despite the lower genetic similarity to the challenge strain, provided comparable or even better protection than the vaccine belonging to the same species. A lower presence of virus in tissues and blood was observed, and the animals vaccinated with this PRR-SV1 MLV were the only ones to develop detectable neutralizing antibodies before challenge (with a significant enhancement after challenge (p<0.05). These results suggest that immunological properties may be more important than genetic similarities for cross protection³.

The study highlighted the potential for cross-protection between strains with varying genetic similarities, indicating the complexity of PRRS vaccine efficacy.

References

- 1. Madapong et al, Vet Microbiology. 2020; 244:108655
- 2. Bonckaert et al, Porcine Health Manag. 2016; 2:12
- 3. Díaz et al., Virology. 2006; 351(2):249-59.

Code assign: IMM-PP-78

^aSignificant increase compared to titer detected at 0 dpi (p = 0.01).